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Abstract
Background: Lewis Y (Le
y) is a blood group-related carbohydrate that is expressed at high surface densities on the majority
of epithelial carcinomas and is a promising target for antibody-based immunotherapy. A humanized Le
y-specific antibody
(hu3S193) has shown encouraging safety, pharmacokinetic and tumor-targeting properties in recently completed Phase I
clinical trials.
Methodology/Principal Findings: We report the three-dimensional structures for both the free (unliganded) and bound
(Le
y tetrasaccharide) hu3S193 Fab from the same crystal grown in the presence of divalent zinc ions. There is no evidence of
significant conformational changes occurring in either the Le
y carbohydrate antigen or the hu3S193 binding site, which
suggests a rigid fit binding mechanism. In the crystal, the hu3S193 Fab molecules are coordinated at their protein-protein
interface by two zinc ions and in solution aggregation of Fab can be initiated by zinc, but not magnesium ions. Dynamic
light scattering revealed that zinc ions could initiate a sharp transition from hu3S193 Fab monomers to large multimeric
aggregates in solution.
Conclusions/Significance: Zinc ions can mediate interactions between hu3S193 Fab in crystals and in solution. Whether
metallic ion mediated aggregation of antibody occurs in vivo is not known, but the present results suggest that similar
clustering mechanisms could occur when hu3S193 binds to Le
y on cells, particularly given the high surface densities of
antigen on the target tumor cells.
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Introduction
Recent studies of the normal biological functions of the Lewis Y
(Le
y or CD174) carbohydrate antigen have revealed new insights
into its role in cellular function [1–3]. This type 2 histo-blood
group related carbohydrate antigen is expressed at high surface
densities on 60% to 90% of carcinomas of the breast, ovary, colon,
lung and prostate [4–6]. Together with its frequent over-
expression on primary and metastatic tumors, its low abundance
and restricted distribution on normal tissues, Le
y represents a
promising target for antibody-based immunotherapeutic ap-
proaches [7,8].
During human development, Le
y is expressed on tissues of the
fetus, placenta [9] and newborn [10,11]. However, in adults Le
y is
either intracellular or at low surface densities on a few tissues
including: hematopoietic precursors, vascular endothelial cells,
and epithelial surfaces of the gastrointestinal tract [7,12–14].
Fucosylated type 2 determinants (Le
x and Le
y) have also been
demonstrated as the major free oligosaccharides in human seminal
plasma [15]. Recently, N-linked Le
y oligosaccharides have been
shown to be present at high levels in the acrosome (a large
intracellular compartment similar to a lysosome) of human sperm,
but are not present on the plasma membrane [3]. Defective or
malformed sperm were shown to display Le
y on the plasma
membrane. Given that both Le
x and Le
y have been shown to
interact with human dendritic cells via DC-SIGN to induce T-cell
tolerance [16], these oligosaccharides may play a role in the
immune privilege of the male reproductive tract [3]. Similarly,
tumors may promote T-cell tolerance by expressing high surface
levels of type 2 Lewis antigens including Le
y. More recently, the
low level expression of Le
y on ICAM-2 of human vascular
endothelial cells has been shown to support adhesion and rolling of
immature dendritic cells and is involved in the initial cell-cell
contacts during angiogenesis [1,2]. The involvement of Le
y in cell
adhesion and angiogenic events, together with the high surface
densities on Le
y-positive cancers, suggest the involvement of this
carbohydrate antigen in tumor migration (ie., metastasis) and
neoangiogenesis [2]. A corollary of these observations is that the
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y-specific therapeutic antibody may
not solely be through antibody-dependent cellular cytotoxicity
(ADCC) and complement-mediated cytotoxicity (CDC), but may
additionally involve direct inhibition of tumor cell migration and
neoangiogenesis.
Early clinical trials with Le
y-specific murine monoclonal
antibodies and antibody-toxin conjugates were limited by
immunogenicity, dose limiting toxicity [17] and unexpected side-
effects like vascular leakage syndrome (LMB-1, murine B3
antibody linked to Pseudomonas exotoxin) [18]. Phase I trials have
now been conducted with Le
y-specific humanized IgG1 mono-
clonals, IGN311 [19] and hu3S193 [20,21], and have shown
encouraging safety, pharmacokinetic and tumor targeting proper-
ties. Trials have also been conducted with a chimeric BR96-
doxorubicin conjugate (SGN-15) in a range of cancer patients with
some modest clinical activity, but some immune responses towards
the BR96-doxorubicin conjugates were noted [22]. Clinical studies
with hu3S193 in a variety of Le
y-expressing cancer patients have
demonstrated that this antibody does not induce human anti-
humanized antibody (HAHA) responses, selectively targets and
accumulates in Le
y-expressing tumors at high concentrations,
retains immune effector function in vivo, and does not show
saturable binding to any normal tissue compartment [20,21].
Against Le
y-expressing tumor cells, hu3S193 has potent in vitro
immune effector functions, including complement-dependent
cytotoxicity (CDC, IC50=1.0 mg/ml) and antibody-dependent
cellular-cytotoxicity (ADCC, IC50=0.5 mg/ml) [23]. Further-
more, hu3S193 is rapidly internalized through the lysosomal/
endosomal pathway in the Le
y-expressing MCF-7 tumor cells [24].
The preferential binding of hu3S193 to tumor cells with high
surface densities of Le
y and lack of binding to normal tissues
expressing lower levels of Le
y suggests that this antibody is
involved in carbohydrate cluster recognition as a first step in tumor
cell killing.
Previously, we determined the crystal structure of hu3S193 Fab
in complex with Le
y at a resolution of 1.9 A ˚ [25]. Since hu3S193
binding of Le
y was almost identical to that of the BR96 antibody,
we proposed that the antibody response to this tumor-associated
antigen was structurally conserved. In a subsequent analysis of all
reported free and bound Lewis system carbohydrates (Le
a,L e
b,
Le
x and Le
y), we confirmed the overall structural similarity and
rigid nature of these carbohydrate antigens [26]. Thus, the free
Le
y conformation closely resembles the biologically active or
antibody-bound state. Herein we report three-dimensional
structures of both the free (unliganded) and bound (Le
y
tetrasaccharide) hu3S193 Fab in the same orthorhombic P212121
crystals, which were grown in the presence of divalent zinc ions.
Comparison of the free and bound Fabs shows that the binding
site of hu3S193 does not undergo significant changes during
complex formation. Furthermore, the findings of a zinc-dependent
Fab dimer in crystals and aggregation in solution induced by Zn
2+
ions, may point towards a role of divalent metallic ions in
antibody-based carbohydrate clustering.
Methods
Preparation and Co-Crystallization of hu3S193 Fab with
the Le
y Tetrasaccharide
The hu3S193 IgG1(k) antibody was produced and purified as
described [23]. The hu3S193 Fab was obtained by plasmin
digestion and purified to homogeneity following protocols reported
earlier [25]. Crystals of hu3S193 Fab were produced in 2 ml sitting
drops in the presence of Le
y by vapor diffusion in a 96-well, round
bottom, sitting-drop plate (Corning, Acton, MA, USA) using the
Crystal Screen HT kit (Hampton Research, Aliso Viejo, CA,
USA). The hu3S193 Fab in 30 mM NaCl, 16 mM Tris-HCl
(pH 8.0) was at 7 mg/ml and Le
y tetrasaccharide (Sigma, St.
Louis, MO, USA) at a fourfold molar excess. Crystals used for data
collection were produced under the following condition: 25% (v/v)
PEG monomethyl ether 550, 0.1 M MES (pH 6.5) and 0.01 M
zinc sulfate.
Collection of X-ray Diffraction Data and Structure
Determination
A single crystal (approximate dimensions of 0.260.160.1 mm)
was transferred to a cryoprotectant solution, comprising the
crystallization condition supplemented with 5% (v/v) glycerol. The
crystal was mounted in a nylon loop and flash-cooled to 100 K in a
N2 cryostream (Cryojet, Oxford Instruments, Abington, Oxford-
shire, UK). X-ray data were obtained using a MicroMax007/R-
Axis IV
++ rotating anode generator system (Rigaku Americas,
Woodlands, TX, USA) operated at 40 kV and 20 mA. The X-rays
were focused to 0.3 mm diameter using Osmic Blue confocal
optics and diffraction images (Dw=0.5u) were captured on an R-
Axis IV
++ detector at a crystal-to-detector distance of 200 mm.
Diffraction data were processed using the HKL program suite
version 1.97.8 [27].
The two hu3S193 Fab molecules were located by molecular
replacement (search model was PDB ID: 1S3K; [25]) using
Molrep, version 9.2 [28], as implemented within the CCP4
program suite, version 5.0.5.2 [29]. After rigid body refinement
and restrained refinement against a maximum likelihood function
(MLF) with Refmac5, the Rwork and Rfree values were 0.31 and 0.41,
respectively. Further fitting of atomic models to electron density
maps and crystallographic refinements were performed with
TURBO-FRODO, version 5.5, (BioGraphics, Marseille, France)
and CNS, version 1.0 [30]. Rigid body refinement of the positions
of the VL:VH and CL:CH1 domain pairs, simulated annealing,
energy minimization, and temperature factor refinement lowered
the Rwork to 0.27 and Rfree to 0.33. After reiterative fitting into
|Fo|2|Fc| electron density maps and crystallographic refinements
the final structure contained: a Le
y tetrasaccharide associated with
Fab1, a glycerol in the binding site of Fab2. In addition, the
structure contained 4 Zn
2+ ions and 143 solvent (water) molecules.
The final coordinates had Rwork and Rfree values of 0.21 and 0.26 at
2.5 A ˚ resolution. A summary of data collection and crystallo-
graphic refinement statistics are presented in Table 1. The 1.9 A ˚
resolution hu3S193 Fab-Le
y complex (PDB ID: 1S3K) used here
for comparison was previously reported [25]. Atomic co-ordinates
and structure factors for the current structure have been deposited
with the Protein Data Bank at the Research Collaboratory for
Structural Bioinformatics http://www.rcsb.org/pdb under the
accession code 3EYV.
Dynamic Light Scattering (DLS)
The DLS measurements were carried out with a Zetasizer Nano
ZS instrument (Malvern Instruments, UK), which was fitted with a
633 nm laser and a single detector located at 173u with respect to
the laser. Samples of hu3S193 Fab were prepared in Tris-buffered
saline (pH 7.4) and titrated with zinc or magnesium chloride.
Immediately before use, samples were centrifuged at 15,850 g at
room temperature for 10 min to remove particulate material. The
supernates were transferred to plastic cuvettes and allowed to
equilibrate at 25 uC for 30 min prior to measurement. The data
were analyzed with Malvern Instrument Dispersion Technology
Software (DTS), version 3.30. Light scattering intensities (I) were
integrated as correlograms (plots of a correlation coefficient,
G(t)=,I(t).I(t+t). versus time, where t= the sampling time of the
Antibody Tumor Recognition
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aggregation. The z-average hydrodynamic diameters (DH) were
determined by the cumulants method [31] as defined in the
international standard for DLS measurements (ISO 13321).
Results
Presence of the Free and Le
y-Bound hu3S193 Fab
Molecules in the Same Crystal
Orthorhombic P212121 crystals of hu3S193 Fab were grown in
the presence the Le
y tetrasaccharide and the crystallographic
structure was determined to 2.5 A ˚ resolution (Table 1). The
asymmetric unit contained two hu3S193 Fab molecules (Fig. 1),
one binding site was in complex with Le
y (Fab1) and the second
binding site contained only a loosely associated glycerol molecule
and a few solvent molecules (Fab2). Thus, the same crystal
contained binding site structures for both the free and Le
y-bound
hu3S193 antibody. Four Zn
2+ ions were located in the asymmetric
unit as strong |Fo|2|Fc| electron density peaks. Two of the Zn
2+
ions were associated with cross-pairing of the hu3S193 Fab
molecules; while the other Zn
2+ ions were located in solvent-
exposed locations at the end of the CL domains (see Fig. 1).
Comparison of the quaternary structures of the originally reported
hu3S193 Fab structure (PDB ID: 1S3K) [25] with the two Fab
structures reported here revealed very similar structures of the
VL:VH and CL:CH1 domain modules, with carbon-alpha (Ca) root-
mean-square deviations (RMSD) of 0.37–0.40 A ˚ for VL:VH (232
residues) and 0.49–0.80 A ˚ for CL:CH1 (196 residues) in pairwise
comparisons. However, the ‘‘elbow bend’’ angles differed between
the 1S3K Fab (136u) and the two Fab molecules in the asymmetric
unit (Fab1, 143u;F a b 2 ,1 4 6 u),indicating a modest degree of flexibility
for the hu3S193 Fab in the V-C ‘‘switch’’ regions (ie., short regions of
polypeptide connecting the V and C domains). The elbow bend
angles of the hu3S139 Fab molecules (136u–146u) are well within the
ranges previously observed for Fab and represent frequently
occurring values for Fab containing k-type light chains [32].
Comparison of the Binding Sites of the Free and Le
y-
Bound hu3S193 Fab Molecules
In the two independent hu3S193 Fab-Le
y complexes (Fab1 and
1S3K), the interactions between binding site residues and Le
y are
nearly identical (Fig. 2 A and C). The only notable difference is the
absence in the Fab1-Le
y complex of a single hydrogen bond
between Asn 28L (ND2 atom) and the Le
y-specific Fuc (O4 atom)
saccharide unit (ie., the a1–2 linked Fuc). The Asn 28L to Fuc
(ND2 to O4) distance in the Fab1-Le
y complex is 3.6 A ˚, compared
to 3.0 A ˚ in the 1S3K complex. Combined with other distances
around the Le
y-specific Fuc, which are consistently slightly larger
in the Fab1-Le
y complex compared to 1S3K, it appears that Le
y is
more loosely bound in crystals grown in the presence of zinc ions.
This observation is supported by the absence of a Le
y ligand in the
binding site of Fab2 (Fig. 2 B). The Fab2 binding site is contains a
few solvent molecules and a glycerol (GOL) molecule, which is
weakly held in place by a single water-mediated hydrogen bond.
No binding site residues of Fab2 interacted directly with the GOL
molecule, which originated from the cryoprotectant solution used
to flash-cool the crystal for X-ray diffraction data collection. The
Le
y ligand either was not bound or was eluted from Fab2 during
transfer to the cryoprotectant, but the Fab2 binding site represents
the unliganded or free hu3S193 Fab.
Overlays of the hu3S193 Fab structures (two in complex with
Le
y and one unliganded Fab) demonstrate almost identical
Figure 1. Ribbons style representation of the two hu3S193 Fab
molecules comprising the asymmetric unit of the orthorhom-
bic P212121 crystals. Fab1 contains the bound Le
y tetrasaccharide
(green), while Fab2 contains a loosely bound glycerol (GOL, orange).
The light (Fab1, yellow; Fab2, pale green) and heavy (Fab1, magenta;
Fab2, dark blue) chains and locations of four divalent zinc ions (cyan)
are indicated.
doi:10.1371/journal.pone.0007777.g001
Table 1. Data collection and crystallographic refinement
statistics.
Parameter Value
a
Data collection
Space group P212121
Unit cell variables
a, b, c (A ˚) 78.8, 101.5, 115.0
a, b, c (u) 90, 90, 90
Resolution range (A ˚) 100–2.50 (2.59–2.5)
Number of unique reflections 31623 (3074)
Percent data completeness 95.8 (94.7)
Average multiplicity 5.5 (5.4)
Rsym 0.073 (0.38)
Mean I/s(I) 23.8 (4.5)
Crystallographic refinement
Rwork 0.212
Rfree 0.263
Ramachandran plot values (%)
Most favored regions 86.6
Additional allowed regions 12.3
Generously allowed regions 0.8
Disallowed regions 0.3
aValues in parentheses refer to the highest resolution shell, 2.59–2.5 A ˚,i nt h e
data. Refinement and stereochemical parameters were compiled from the CNS
program suite, version 1.0 [30] or PROCHECK version 3.3 [59].
doi:10.1371/journal.pone.0007777.t001
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y
tetrasaccharide (Fig. 2 D). Thus, the binding site of hu3193 does
not appear to have undergone conformational changes during
complex formation with Le
y. We previously reported that the
hu3S193-bound conformation of Le
y was fundamentally the same
as the known free and bound conformations of Le
y and other
Lewis system carbohydrates [26]. Similarly, the bound conforma-
tions of Le
y in 1S3K and Fab1 were essentially the same (Table 2),
which further supports the idea of the rigid character of the Le
y
carbohydrate determinant. Note that the slight variation in the
Fuca1–2Gal glycosidic linkage (Table 2) is compatible with the
small differences observed in the interactions between the Le
y-
specific Fuc and the hu3S193 binding site for the 1S3K and Fab1
structures (Fig. 2 A and C).
At 1.9 A ˚ resolution an extensive solvent network of 13 ordered
water molecules surrounds the Le
y tetrasaccharide in complex
with hu3S193 Fab [25]. The ordered solvent was involved in
hydrogen bonding to protein and carbohydrate residues (7 water
molecules) and in forming more extended hydrogen bonding
networks (6 water molecules), which led to greater complemen-
tarity between Le
y and the hu3S193 binding site [26]. In the
vicinity of the Fab1-Le
y interaction, two ordered solvent molecules
were observed in the 2.5 A ˚ resolution electron density maps (Fig. 2
A) and both occupied the same locations as in the 1S3K structure
(Fig. 2 C). Without the Le
y ligand, the hu3S193 binding site
contained 4 ordered water molecules and a glycerol. One water
molecule in the unliganded hu3S193 binding site occupied a
location (near tyrosines 32H and 33H) where the N-acetyl group
of the Le
y tetrasaccharide binds and could have been displaced
during complex formation (Fig. 2 A and B). However, none of the
water molecules in the unliganded binding site occupied
comparable locations to solvent molecules in the hu3S193
complexes with Le
y. Thus, it is likely that the water molecules
Figure 2. Comparison of the binding sites of three distinct structures of hu3S193 Fab. A) Fab1 containing a bound Le
y tetrasaccharide
(contact residues in cyan); B) Fab2 containing a loosely bound glycerol and solvent (contact residues highlighted in pale green); C) Structure of
hu3S193 Fab in complex with Le
y (contact residues in magenta) determined at 1.9 A ˚ resolution (PDB ID: 1S3K) [25]; and, D) Overlays of binding site
residues for the three different hu3S193 Fabs. The Le
y and GOL ligands are colored by atom type (C, yellow; N, blue; O, red). Ordered solvent
molecules participating in the interactions with ligand are shown (panels A–C, pale blue) and hydrogen bonds are drawn as dashed lines (black).
Binding site residues are numbered according to the Kabat scheme.
doi:10.1371/journal.pone.0007777.g002
Table 2. Conformational characteristics of hu3S193-bound
Le
y tetrasaccharides.
Fab-Ley
complex Fuca1-2Gal
a Galb1-4GlcNAc Fuca1-3GlcNAc
wywywy
1S3K 278.1 140.4 277.6 139.2 277.8 2103.4
Fab1 274.8 132.9 278.1 134.2 277.5 2102.5
aThe glycosidic dihedral angles w and y (u) are defined as O52C12O12Cx and
C12O12Cx2Cx21, respectively. Values of glycosidic dihedrals for other free
and bound Lewis system oligosaccharides were previously reported [26].
doi:10.1371/journal.pone.0007777.t002
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y carbohydrate or are recruited to the
interaction rather than being already present in the hu3S193
binding site.
Zinc-Dependent Crystallographic Dimers of hu3S193 Fab
Suggest a Possible Role of Divalent Metal Ions in
Carbohydrate Cluster Recognition
The hu3S193 Fab molecules contain four Zn
2+ ions bound in
two types of environment. Firstly, protein interface zinc-binding
sites are formed between the Fab1 and Fab2 molecules and
involve the tetravalent coordination by Fab residues (Fig. 3 A and
C). Asparagines 142 and 143 of the light chain (A or L) and His
170 of the heavy chain (B or H) of one Fab form a pocket in the
CL:CH1 domain interface that binds a Zn
2+ ion, which accepts
Glu 1 from the heavy chain of the second Fab. In one site, a water
molecule acts as a fifth ligand for the Zn
2+ ion (Fig. 3 A), but this
was not observed in the second protein interface zinc-binding site
(Fig. 3 C). Access for the water ligand is possible since the
coordination of zinc is distorted from tetrahedral geometry. The
two zinc ions form part of a larger protein-protein interface
between the hu3S193 Fab molecules in the asymmetric unit.
Secondly, surface-located zinc sites were identified in the hu3S193
k-type light chains where Zn
2+ ions interacted bivalently with His
194L and Asp190L (Fab1; Fig. 3 B) or monovalently with His
194L (Fab2; Fig. 3 D). Rather than being buried at a protein-
protein interface the surface-located zinc ions line solvent channels
in the orthorhombic P212121 crystals and are at least 4 A ˚ from any
symmetry related Fab.
The presence in crystals of zinc-stabilized hu3S193 Fab
homodimers led us to test in solution by DLS the effect of zinc
ions on the Fab. In solution, hu3S193 Fab (,15 mM) aggregated
in the presence of 40 and 50 mM ZnCl2, but not at lower
concentrations or at any concentration of MgCl2 tested (Fig. 4).
Interestingly, zinc-induced aggregation of the hu3S193 Fab
required at least two molar equivalents of Zn
2+ ions, which is
similar to the four Zn
2+ ions found, associated with the two
hu3S193 Fab molecules in the asymmetric unit of the crystals.
The zinc ion induced changes in solution of hu3S193 Fab were
further characterized by DLS by monitoring the z-average
hydrodynamic diameters (DH) in the presence of divalent metallic
ions (Fig. 5). Without any metallic ions hu3S193 Fab behaved as a
monomer with DH in the range of 5.3 nm to 7.1 nm. Similar DH
values were obtained at all MgCl2 concentrations and when ZnCl2
was between 10 mM and 30 mM. A sharp transition occurred at
40 mM ZnCl2 where the hu3S193 Fab formed large aggregates
with a mean DH value of 211.9 nm (range of 92.8 nm to
333.9 nm). When the ZnCl2 was raised to 50 mM the hu3S193
Figure 3. Coordination of divalent zinc ions in orthorhombic crystals of hu3S193 Fab. Two Zn
2+ ions (A and C) are involved in tetravalent
coordination with residues from the two independent crystallographic Fabs. At one site (A) a water molecule interacts with the Zn
2+ ion, but this
interaction does not occur at the second site (C). An additional two Zn
2+ ions were observed (B and D) and were coordinated by Asp 190L and His
194L (Fab1) or only by His 194A (Fab2) due to small differences in the polypeptide conformation between Fab1 and Fab2.
doi:10.1371/journal.pone.0007777.g003
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547.8 nm). The zinc-mediated aggregates of hu3S193 Fab are
substantially larger than polymeric IgM (molecular mass
.950 kDa or 19 S), which we have previously shown to have a
z-average DH of between 34 and 37 nm [33,34]. Thus, in solution
zinc ions can mediate the formation of multimeric aggregates of
hu3S193 Fab, but does not appear to produce smaller ordered
multimers such as the dimers observed in crystals.
While the physiological levels of Zn
2+ in blood plasma is around
20 mM, certain tissues and cellular compartments have been
shown to have dramatically higher levels of Zn
2+ [35–39].
Furthermore, intracellular Zn
2+ fluxes have been recently shown
to be involved in lipopolysaccharide-induced signals in human
monocytes [40], which supports the concept that the local
concentration of zinc ions can rapidly change in biological
microenvironments. Thus, the 40 mM ZnCl2 required for
aggregation of hu3S193 Fab in solution indicates that in vivo
aggregation should not occur in the blood plasma, but would
possibly be induced in certain tissue or cellular compartments
where Zn
2+ ions can be at significantly higher concentrations.
Discussion
In the current work, we were presented with an opportunity to
examine the three-dimensional structures of both the free and Le
y-
bound hu3S193 binding sites from the same crystal. Apart from
the subtle differences in solvent structure and minor adjustments of
the Le
y-specific Fuc residue, the binding sites for the three
hu3S193 structures were identical (see Fig. 2 D). Taken together
with the established rigid nature of the Le
y carbohydrate [26], the
available data strongly supports the binding of the Le
y antigen by
the hu3S193 antibody to resemble the fit of an unbendable key
into a rigid lock. This finding is in contrast to the now commonly
held view that both antigen and antibody frequently undergo
conformational changes or induced fit upon binding [41–46].
Similarly, carbohydrates have traditionally been viewed as more
flexible and mobile in solution when compared to globular
proteins. Thus, the interaction between the hu3S193 antibody and
Le
y carbohydrate determinant has made us revisit the lock-and-
key concept as a possible mechanism for antibody recognition of
carbohydrate antigens, particularly in Le
y-expressing tumors.
Reynolds and colleagues recently examined the hydration
features of free type 2 Lewis antigens (Le
x and Le
y) by molecular
dynamics (MD) simulations [47]. In this study, the solvated
carbohydrate determinants remained relatively inflexible or rigid
during extensive MD simulations, confirming earlier observations
that the free conformation is representative of the biologically
active state for Lewis system antigens (reviewed in [26]).
Interestingly, the water molecule bridging events or solvent
structure around free Le
y observed by the MD simulations were
mostly represented by water molecules and a few binding site
residues in the hu3S193 Fab-Le
y complex at 1.9 A ˚ resolution
[25,47]. For the present complex (Fab1-Le
y) that was determined
at a resolution of 2.5 A ˚, we identified two of the same bridging
water molecules and these were buried in the carbohydrate-
antibody interface. Since most of the water molecules surrounding
Le
y are not buried in the binding site, it is possible that these were
simply not observed in crystals at a resolution of 2.5 A ˚. However,
the finding of key water molecules involved in the hu3S193
interaction with Le
y supports the conclusion that solvent mediates
the rigid conformational properties of this carbohydrate epitope
and is important for antibody recognition. Furthermore, the
hydrated structure of Le
y antigens when presented on the surface
of tumor cells is likely to snugly fit the hu3S193 binding site
without the need for displacement of the majority of the water
molecules from the carbohydrate.
The in vivo specificity of hu3S193 for Le
y on tumor cells and no
saturable binding to any normal tissue compartment [20],
indicates that the presentation of Le
y determinants by tumor cells
is different from normal tissues. Clearly, Le
y epitopes are both
expressed in tumors at relatively high surface densities and are
aberrantly expressed on various membrane-bound glycoproteins
Figure 4. Divalent zinc ion mediated aggregation of the
hu3S193 Fab. Dynamic light scattering was used to monitor time-
dependent fluctuations (correlograms) in scattered light intensity for
samples of hu3S193 Fab (,15 mM) in the presence of: A) ZnCl2; and, B)
MgCl2. Final concentrations of the divalent metal ions were 0 mM (short
dash), 10 mM (dash-dot), 20 mM (dots), 40 mM (dash) and 50 mM (solid).
doi:10.1371/journal.pone.0007777.g004
Figure 5. Changes in size of hu3S193 Fab in the presence of
zinc ions monitored by DLS. The z-average DH (nm) was determined
for hu3S193 Fab samples in the presence of increasing concentrations
of ZnCl2 (black) or MgCl2 (white). Mean values (n=3) are shown and
error bars represent three standard deviations.
doi:10.1371/journal.pone.0007777.g005
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candidate antigens for tumor immunotherapy [48–53]. Our
findings of a zinc-dependent homodimer of hu3S193 Fab in
crystals and the corresponding aggregation of Fab in solution,
provides the first evidence for a possible new mechanism of
carbohydrate cluster recognition. We propose that binding of
hu3S193 to dense clusters of Le
y on tumor cells could be further
stabilized by Zn
2+ or other divalent metallic ions resulting in an
increase in the avidity of the interaction. Similarly the role of zinc
in protein-protein interactions has been described for several other
biological systems [54–57]. The low surface densities of Le
y
carbohydrates on normal tissues would not be suitable for lateral
zinc-mediated interactions to occur between neighboring antibod-
ies, which could explain the evident lack of binding by hu3S193 to
normal Le
y-expressing tissues.
Another immunological solution for specific antibody binding to
dense clusters has been reported for the 2G12 IgG, which is highly
specific for the complex oligomannose glycans that decorate the
‘‘silent face’’ HIV-1 gp120 [58]. Both the 2G12 Fab and the intact
antibody has been shown to contain domain-swapped Fab
homodimers, where VH domains from each Fab associate with
the corresponding VL in the adjacent Fab to form an extended
surface for multivalent carbohydrate binding. While domain-
swapped antibodies represent an elegant mechanism for carbohy-
drate cluster recognition, these are likely to be rare and difficult to
elicit by standard immunization strategies [58]. Our proposed
metallic ion mediated mechanism for Le
y carbohydrate cluster
recognition by hu3S193 may be more general since most IgG/k
antibodies have the residues involved in coordinating Zn
2+ by
hu3S193 Fab.
Understanding the mechanism of action of a candidate
therapeutic antibody against solid tumors requires a detailed
physicochemical understanding of specificity and immune effector
functions as well as the in vivo pharmacokinetics and biological
activity in normal and tumor sites. We have shown that the
binding specificity for Le
y by hu3S193 does not involve
conformational changes and the interaction mimics the hydration
patterns of free Le
y antigens. Additionally, the structural results
presented here indicate a new potential mechanism for hu3S193
selective recognition of Le
y on tumor cells as opposed to normal
tissues, which is based on metallic ion mediated carbohydrate
cluster recognition.
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